By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


H3 Biomedicine Inc. 

300 Technology Square, Fifth Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-252-5000 Fax: n/a


Company News
H3 Biomedicine Granted Orphan Drug Designation Of H3B-8800 For Treatment Of Acute Myelogenous Leukemia And Chronic Myelomonocytic Leukemia 8/14/2017 6:28:36 AM
H3 Biomedicine And University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism In Muscle-Invasive Bladder Cancer 7/24/2017 7:40:14 AM
H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research Around Splicing Modulators Published In Current Issue Of Nature Communications 6/1/2017 6:27:49 AM
H3 Biomedicine Appoints Lihua Yu, Ph.D., To Chief Data Sciences Officer 5/1/2017 6:02:04 AM
H3 Biomedicine Extends Collaboration With Foundation Medicine, Inc. (FMI) To Develop Precision Therapies For Cancer 4/20/2017 6:13:03 AM
H3 Biomedicine Presents New Data From Its RNA Splicing Platform At AACR 4/4/2017 7:19:41 AM
H3 Biomedicine Announces Appointment Of Peter G. Smith, Ph. D., To Chief Scientific Officer 2/21/2017 8:27:16 AM
H3 Biomedicine Announces Data From Lead Development Program Of H3B-8800 In Pre-Clinical Models Of Hematologic Cancers 12/6/2016 12:21:04 PM
Cancer Genetics (CGIX) Selected By H3 Biomedicine To Provide Biomarker Discovery And Testing For A Global Drug Development Program In Hematologic Cancers 7/18/2016 8:03:16 AM
H3 Biomedicine Announces Appointment Of Tarek Sahmoud As Chief Medical Officer 6/1/2016 4:44:38 PM